Local displacement within the Achilles tendon induced by electrical stimulation of the single gastrocnemius muscles.

BACKGROUND: The Achilles tendon consists of three subtendons, but their functional meaning is still unknown. There are several approaches for the examination in-vivo using sonographic imaging, however, there is no approach for in-vivo examination with respect to the single subtendons of the m. triceps surae. The study's aim was to reveal the single subtendons of the m. triceps surae. METHODS: The Achilles tendon of 17 subjects was analysed. The muscles (m. gastrocnemius lateralis and medialis) were stimulated separately using neuromuscular electrical stimulation. The intensity of muscle contraction was controlled using electromyographic data. Sonographic videos of the Achilles tendon were recorded during muscle contraction. A speckle tracking algorithm was used to analyse the moving areas within the Achilles tendon during the initial phase of contraction. FINDINGS: The muscles were activated at 10-20% of the maximal M-wave. Isolated contraction of m. gastrocnemius lateralis led to local displacement in the lateral part of the Achilles tendon's cross-section whereas isolated contraction of m. gastrocnemius medialis led to displacement in the medial part and to a larger size of the area where initial displacement took place (m. gastrocnemius lateralis to medialis approximately 1:2). INTERPRETATION: The results demonstrate that isolated contractions of m. gastrocnemius lateralis and medialis lead to individual displacements which significantly differ. The differences in position and size of the area of the local displacement indicate an independent individual function. Unlike other studies generally investigating the AT in-vivo using muscle stimulation and ultrasonic imaging, this study investigated the AT's cross-section which had never been investigated before.

Family Correlates of Adjustment Profiles in Mexican-Origin Female Adolescents.

This study used a person-centered approach to examine patterns of adjustment along psychological (i.e., depression, self-esteem, anxiety) and academic (i.e., academic motivation) domains in a sample (N = 338) of Mexican-origin female adolescents. Four adjustment profiles were identified. A High Functioning (n = 173) group, which exhibited high positive adjustment and academic functioning, an Average Functioning (n = 83) group, who exhibited average psychological and academic functioning, an Academically Oriented and Stressed (n = 19) group, who exhibited high academic motivation, but poor psychological functioning in anxiety and negative affect, and a Low Functioning" (n = 25) group, who exhibited poor adjustment overall. Further, paternal and maternal parenting characteristics (i.e., autonomy granting, parent-adolescent conflict, and supportive parenting) were differentially related to Mexican-origin female adolescents' profiles, providing further evidence for the existence of the profiles. Results contribute to the current literature on Latino adolescents and highlight the importance of examining psychological and academic domains concurrently to determine how these two domains of adjustment are linked among this population.

Characterization of potential outcome measures for future clinical trials in fragile X syndrome.

Clinical trials targeting recently elucidated synaptic defects in fragile X syndrome (FXS) will require outcome measures capable of assessing short-term changes in cognitive functioning. Potentially useful measures for FXS were evaluated here in a test-retest setting in males and females with FXS (N = 46). Good reproducibility, determined by an interclass correlation (ICC) or weighted kappa (kappa) of 0.7-0.9 was seen for RBANS List and Story Memory, NEPSY Tower, Woodcock-Johnson Spatial Relations and the commissions score from the Carolina Fragile X Project Continuous Performance Test (CPT). This study demonstrates the feasibility of generating test profiles containing reliability data, ability levels required for test performance, and refusal rates to assist with choice of outcome measures in FXS and other cohorts with cognitive disability.

Progression of tremor and ataxia in male carriers of the FMR1 premutation.

Premutation alleles of the fragile X mental retardation 1 (FMR1) gene give rise to a late-onset movement disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), characterized by progressive intention tremor and gait ataxia, with associated dementia and global brain atrophy. The natural history of FXTAS is largely unknown. To address this issue, a family-based, retrospective, longitudinal study was conducted with a cohort of 55 male premutation carriers. Analysis of the progression of the major motor signs of FXTAS, tremor and ataxia, shows that tremor usually occurs first, with median onset at approximately 60 years of age. From the onset of the initial motor sign, median delay of onset of ataxia was 2 years; onset of falls, 6 years; dependence on a walking aid, 15 years; and death, 21 years. Preliminary data on life expectancy are variable, with a range from 5 to 25 years.

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.

A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). After baseline screening, subjects with FXS (n = 49) underwent a 1-week placebo lead-in and then were randomized to study drug or placebo for a 4-week period. Cognitive and behavioral outcome measures were administered prior to treatment, at the end of treatment, and 2 weeks posttreatment. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. There was a 12.5% frequency of allergic rash in the CX516 group and 1 subject developed a substantial rash. There was also no significant improvement in memory, the primary outcome measure, or in secondary measures of language, attention/executive function, behavior, and overall functioning in CX516-treated subjects compared to placebo. This study did demonstrate that many outcome measures were reproducible in this test-retest setting for the FXS population, yet some were too difficult or variable. Adult subjects with FXS were able to complete an intensive clinical trial, and some valid outcome measures were identified for future FXS trial design. Problems with potency of CX516 in other studies have suggested dosing may have been inadequate for therapeutic effect and thus it remains unclear whether modulation of AMPA-mediated neurotransmission is a viable therapeutic strategy for the treatment of FXS.